Loading...
skip to Main Content

This page offers you with an array of useful resources related to COVID-19 and the liver, including articles, accounts from healthcare professionals, calls for abstracts, and statements.
You are welcome to send suggestions of materials to include to us at marcomms@easloffice.eu

EASL webinars

EASL has launched a series of webinars relating to COVID-19. The participants are world-renowned scientists and clinicians that discuss and share their knowledge about the latest developments of the virus.

EASL-WHO webinar on COVID-19 and the liver

Don’t miss this special webinar on COVID-19 and the liver organised by EASL and the World Health Organization (WHO).

Listen to a panel of leading international experts and clinicians in hepatology and virology presenting the latest information on the COVID-19 pandemic, the WHO response, and how the pandemic is affecting the care of people with liver disease and viral hepatitis, both from a clinical and public health perspective. Then hear from frontline clinicians and programme managers from different countries on their experiences in the COVID-19 national response, and in managing the impact on hepatitis services during the current crisis. Viewers submitted their questions from around the world. You can read the Q&A, with expert answers.

EASL Campus series of webinars on COVID-19 and the liver

Limited knowledge on COVID-19 has evidenced the importance of sharing up-to-date information. Working with world-renowned experts, EASL has launched a series of open-access webinars relating to COVID-19 and the liver. Watch the webinars and stay tuned for more.

1. Virological Aspects of COVID-19
2. Viral markers and the diagnosis of COVID-19
3. Viral testing and the immune response to COVID-19

EASL, ESOT-ELITA and ILTS joint webinar

A joint webinar on the impact of COVID-19 on liver transplantation. ESOT-ELITA, EASL and ILTS speakers discuss the effects of the pandemic on liver transplantation in Europe and in the United States as well as the response of medical societies in regard to education.

Watch the COVID-19 & liver transplantation webinar.

Testimonials on dealing with the public health crisis

EASL Viewpoints are testimonials, interviews, and videos from healthcare professionals sharing life from the frontlines, across Europe.

In their testimonials, hepatologists, liver nurses, researchers, and academics tell how their working life has been affected by COVID-19 and what might be to come.

France, Italy, Portugal, Sweden, the UK… and more to come – watch the videos, read the interviews, and get to meet members of the hepatology community.

Access EASL Viewpoints

News from the EASL supported COVID-Hep registry

Press release, 21/05/2020

A new international study has found increased mortality rates from COVID-19 among people with chronic liver disease and cirrhosis and has called for patients with worsening liver function to be tested for coronavirus.

The researchers, led by teams at Oxford University Hospitals NHS Foundation Trust and the University of North Carolina, set up an international registry (the EASL supported COVID-hep registry, see below) to collect clinical details of patients with chronic liver disease and cirrhosis who develop COVID-19. Between 25 March 2020 and 20 April 2020, 152 cases were submitted to the registry, over 95% of which were hospitalised. Patients with cirrhosis had poor outcomes with an overall death rate of 40 percent. Those with advanced disease called decompensated cirrhosis had the highest rate of death (between 43 and 63 percent), compared with 12 percent for patients with liver disease but without cirrhosis.

Read more.

The EASL supported COVID-Hep registry was launched at the University of Oxford, UK on 23 March 2020. The registry is collecting data on patients, with liver disease at any stage or liver transplants, that have also developed laboratory-confirmed COVID-19. On 21 May, a study based on the first 152 consecutive submissions was published in the Journal of Hepatology.

As of 22 September, data collected (combined with data from SECURE-cirrhosis who are covering the Americas, China, Japan, and Korea) has grown to 1,335 submissions, constituting 1,149 cases and 232 deaths; 545 with cirrhosis
and 170 liver transplant recipients. Browse the weekly updates and downloadable reports.

To find out more or make a submission, visit COVID-Hep. You can also request updates by email.

Read more

Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID Position Paper

EASL-ESCMID Position Paper: a review, six months into the pandemic

Six months into the COVID-19 pandemic, an article has been published in JHEP Reports to provide guidance for physicians involved in the care of patients with chronic liver disease. It serves as an update, summarising the evidence for liver disease involvement during COVID-19 and providing recommendations on how to return to routine care wherever possible.

EASL-ESCMID-covid-statement

In response to the COVID-19 pandemic, EASL and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) have issued a Position Paper providing recommendations for clinicians on caring for patients with liver diseases and for liver transplant recipients. The joint Position Paper also provides a flowchart and an overview of current treatment options, to help clinicians with decision-making during this resource-strapped time.

External resources on COVID-19

BioMed Alliance submits Joint Statement to EU leaders, as COVID-19 threatens medical associations

biomed-alliance-cover

Subsequent to the disruption caused by the COVID-19 pandemic, EASL and 32 other leading European medical associations – together forming the Biomedical Alliance in Europe (BioMed Alliance) – have submitted a joint statement to EU leaders.

Read more 

Latest news from the community

@tom_marjot @LancetGastroHep @AASLDtweets @EASLedu @massimoiava @CholestasisDoc @BritSocGastro @EuropeLiver @LiverTrust @phil_newsome7 @EleanorBarnesOx COMING SOON - updated @SecureCirrhosis and @CovidHep report form with some important additions, including post-vaccination SARS-CoV-2 infection.

Case submissions still ongoing (n=1300), please submit via:
https://www.covid-hep.net/ https://covidcirrhosis.web.unc.edu/

More preparation for #liver cancer Summit by @EASLnews This session will deal with imaging and pathology diagnosis, future of t AI and the risks of overdiagnosis and overtreatment. Will be fun to debate with @VChernyakMD @tom_luedde, M Ronot and S Thung!! @AASLDtweets @ILCAnews

🕐 It's a countdown. Only 3 weeks left till Digital #LiverCancerSummit 2021 starts!

Join hundreds of delegates already registered & 60+ speakers, recognised as some of the biggest names in this field.

Register today! https://www.easl.eu/dlcs2021

More preparation for #liver cancer Summit by @EASLnews This session will deal with imaging and pathology diagnosis, future of t AI and the risks of overdiagnosis and overtreatment. Will be fun to debate with @VChernyakMD @tom_luedde, M Ronot and S Thung!! @AASLDtweets @ILCAnews

Getting ready for the #livercancer Summit by @EASLnews together with @NaultJc @nicole_rich8 @mcolombo46 and @HepatoEpi . Will be digital, but not prevent an active debate around hot topics and current state of the art knowledge. @AASLDtweets @ILCAnews @AEEHLiver

@ebtapper @KingsCollegeNHS @KCLImmunoMicro @KingsEcho @AASLDtweets @EASLedu @JasmohanBajaj @djosh78 Pregnancy Cirrhosis Tweetorial...
1. Planning is key
2. Optimise portal hypertension mgt
3. Endo pre-pregnancy
4. Stratify according to MELD, ALBI, APRI and platelets
5. Second trimester endo if ongoing varices
6. Plan delivery

@ebtapper @AASLDtweets

Portopulmonary hypertension is a rare but serious complication of portal hypertension or portosystemic shunting.

Read how 6 cases of paediatric #portopulmonary #hypertension were managed in a specialised center @Hopitaux_unige.

👉 https://bit.ly/3lyl4LC
#livertwitter

Single cell analysis of tumour samples enables to characterize cancer cell subpopulations & identify new targets for #immunotherapy & personalized therapies.

Read the applications in #livercancer in this review by @XinWang77 @theNCI @NCIResearchCtr

👉https://bit.ly/3odPYej

Egypt has a major #HCV burden. Researchers reported 84.6% reduction in incidence of new HCV infections in 9 villages in rural Egypt compared to previous estimate, following an HCV prevention & treat programme in 2015.

Read at https://bit.ly/3gyhpN0
#NOhep

Back To Top